220 related articles for article (PubMed ID: 32082304)
1. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC.
Nigro A; Ricciardi L; Salvato I; Sabbatino F; Vitale M; Crescenzi MA; Montico B; Triggiani M; Pepe S; Stellato C; Casolaro V; Dal Col J
Front Immunol; 2019; 10():3135. PubMed ID: 32082304
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.
Lu J; Li J; Lin Z; Li H; Lou L; Ding W; Ouyang S; Wu Y; Wen Y; Chen X; Yue P; Wang Y; Liu P; Lu J; Zhang J; Feng W; Zhang X
Cancer Lett; 2023 Jun; 564():216205. PubMed ID: 37146936
[TBL] [Abstract][Full Text] [Related]
3. EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer.
Wu PS; Lin MH; Hsiao JC; Lin PY; Pan SH; Chen YJ
Mol Cell Proteomics; 2023 Sep; 22(9):100624. PubMed ID: 37495186
[TBL] [Abstract][Full Text] [Related]
4. miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37.
Kim MS; Kim SH; Yang SH; Kim MS
Cancer Res Treat; 2022 Apr; 54(2):445-457. PubMed ID: 34352998
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.
Shiiya A; Noguchi T; Tomaru U; Ariga S; Takashima Y; Ohhara Y; Taguchi J; Takeuchi S; Shimizu Y; Kinoshita I; Koizumi T; Matsuno Y; Shinagawa N; Sakakibara-Konishi J; Dosaka-Akita H
Cancer Sci; 2023 Apr; 114(4):1270-1283. PubMed ID: 36529523
[TBL] [Abstract][Full Text] [Related]
6. The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression.
Ren S; Zhu Y; Wang S; Zhang Q; Zhang N; Zou X; Wei C; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(1):81-90. PubMed ID: 36471952
[TBL] [Abstract][Full Text] [Related]
7. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.
Cao D; Chen D; Xia JN; Wang WY; Zhu GY; Chen LW; Zhang C; Tan B; Li H; Li YW
Biomed Pharmacother; 2022 Nov; 155():113705. PubMed ID: 36271541
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of gefitinib and hematoporphyrin by aptamer-modified fluorinated dendrimer for hypoxia alleviation and enhanced synergistic chemo-photodynamic therapy of NSCLC.
Zhu F; Xu L; Li X; Li Z; Wang J; Chen H; Li X; Gao Y
Eur J Pharm Sci; 2021 Dec; 167():106004. PubMed ID: 34520834
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
Guo H; Zhang X; Xie S; Chen T; Xie D; Cai Y; Cui D; Wang L; Chen W; Wang X
Int J Oncol; 2022 Dec; 61(6):. PubMed ID: 36205136
[TBL] [Abstract][Full Text] [Related]
10. Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer.
Huang JQ; Duan LX; Liu QY; Li HF; Hu AP; Song JW; Lin C; Huang B; Yao D; Peng B; Sun Y; Wen Y; Yang L; Xu X; Gong LY
Oncogene; 2023 Apr; 42(15):1233-1246. PubMed ID: 36869126
[TBL] [Abstract][Full Text] [Related]
11. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer.
Yu WB; Chen YC; Huang CY; Ye ZH; Shi W; Zhu H; Shi JJ; Chen J; Lu JJ
Front Med; 2023 Feb; 17(1):105-118. PubMed ID: 36414917
[TBL] [Abstract][Full Text] [Related]
12. miR-1/133a and miR-206/133b clusters overcome HGF induced gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations.
Jiao D; Jiang C; Zhu L; Zheng J; Liu X; Liu X; Chen J; Tang X; Chen Q
J Drug Target; 2021 Dec; 29(10):1111-1117. PubMed ID: 33955799
[TBL] [Abstract][Full Text] [Related]
13. An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells.
Si Y; Pei X; Wang X; Han Q; Xu C; Zhang B
Protein Pept Lett; 2021; 28(11):1290-1297. PubMed ID: 34602035
[TBL] [Abstract][Full Text] [Related]
14. ZYZ384 suppresses the growth of EGFR-mutant non-small cell lung cancer by activating JNK/MAPK signaling pathway.
Nie XW; Nasim AA; Yao XJ; Fan XX
Chem Biol Drug Des; 2024 Jan; 103(1):e14408. PubMed ID: 38009559
[TBL] [Abstract][Full Text] [Related]
15. Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region.
He S; Shi J; Zhou H; Li Q; Wu L
Cancer Gene Ther; 2022 Nov; 29(11):1686-1696. PubMed ID: 35701616
[TBL] [Abstract][Full Text] [Related]
16. EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.
Hu LY; Zhuang WT; Chen MJ; Liao J; Wu DF; Zhang YX; Pang LL; Huang YH; Mao TQ; Yang MJ; Peng PJ; Liang JX; Chen L; Zeng LJ; Zhang L; Fang WF
J Thorac Oncol; 2024 Mar; ():. PubMed ID: 38553005
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.
Ahmadi A; Mohammadnejadi E; Razzaghi-Asl N
Comput Biol Med; 2023 Sep; 163():107204. PubMed ID: 37421739
[TBL] [Abstract][Full Text] [Related]
18. Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells.
Li W; Wang H; Yang Y; Zhao T; Zhang Z; Tian Y; Shi Z; Peng X; Li F; Feng Y; Zhang L; Jiang G; Zhang F
Proteomics; 2018 Aug; 18(15):e1700388. PubMed ID: 29901268
[TBL] [Abstract][Full Text] [Related]
19. Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer.
Zhang C; Lu X; Liu X; Xu J; Li J; Qu T; Dai J; Guo R
Oxid Med Cell Longev; 2023; 2023():1367938. PubMed ID: 36760347
[TBL] [Abstract][Full Text] [Related]
20. CRL2
Liu Y; Luo Y; Yan S; Lian YF; Wu S; Xu M; Feng L; Zhang X; Li R; Zhang X; Feng QS; Zeng YX; Zhang H
Oncogene; 2022 May; 41(22):3104-3117. PubMed ID: 35468939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
